EMA/557297/2019

European Medicines Agency decision

P/0373/2019

of 22 November 2019

on the acceptance of a modification of an agreed paediatric investigation plan for avatrombopag (maleate) (Doptelet), (EMEA-001136-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0373/2019

of 22 November 2019

on the acceptance of a modification of an agreed paediatric investigation plan for avatrombopag (maleate) (Doptelet), (EMEA-001136-PIP01-11-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0309/2011 issued on 20 December 2011,

Having regard to the application submitted by Dova Pharmaceuticals Ireland Limited on 12 July 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for avatrombopag (maleate) (Doptelet), film-coated tablet, powder for oral suspension, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Dova Pharmaceuticals Ireland Limited, 6th Floor, 2 Grand Canal Square, D02 A342 - Dublin, Ireland.

EMA/PDCO/412529/2019
Amsterdam, 18 October 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001136-PIP01-11-M01

Scope of the application

Active substance(s):

Avatrombopag (maleate)

Invented name:

Doptelet

Condition(s):

Treatment of idiopathic thrombocytopenic purpura

Treatment of thrombocytopenic purpura secondary to liver disease

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Powder for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Dova Pharmaceuticals Ireland Limited

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Dova Pharmaceuticals Ireland Limited submitted to the European Medicines Agency on 12 July 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0309/2011 issued on 20 December 2011.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 20 August 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Idiopathic Thrombocytopenic Purpura

The waiver applies to:

- infants from birth to less than 1 years of age;
- film-coated tablet, powder for oral suspension, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

1.2. Condition:

Treatment of Thrombocytopenic Purpura Secondary to Liver Disease

The waiver applies to:

- all paediatric subsets from birth to less than 18 years of age;
- film-coated tablet, powder for oral suspension, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of Idiopathic Thrombocytopenic Purpura

2.1.1. Indication(s) targeted by the PIP

Treatment of thrombocytopenia in patients aged 1 year to less than 18 years with chronic immune (idiopathic) thrombocytopenic purpura (ITP), who have had insufficient response to at least one prior ITP treatment.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film coated tablet

Powder for oral suspension

2.1.4. Studies

Area	Number of studies	Description
Quality	2	Study 1: Development of an age appropriate pharmaceutical form for oral use Study 2: Bioavailability study in healthy adults.
Non-clinical	2	Study 3: 4-week dose range finding oral toxicity study in juvenile rats. Study 4: 10-week oral toxicity study in juvenile rats followed by a 4-week recovery period.
Clinical	1	Study 5: Randomized, double-blind, placebo-controlled, parallel group trial to assess efficacy, PK/PD, and safety of avatrombopag (maleate) (E5501) in children with chronic idiopathic thrombocytopenic purpura.
Extrapolation, modelling and simulation studies	1	Study 6: Population Pharmacokinetic/ Pharmacodynamic (PopPKPD) study to predict initial paediatric doses to be used in further clinical studies This study was introduced during modification EMEA-001136-PIP01-11-M01

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By April 2025.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Thrombocytopenia Purpura secondary to liver disease

Authorised indication(s):

- Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use